Avanir Pharmaceuticals (AVNR) jumps 14% premarket after the Committee for Medicinal Products for...

|About: Avanir Pharmaceuticals, Inc (AVNR)|By:, SA News Editor

Avanir Pharmaceuticals (AVNR) jumps 14% premarket after the Committee for Medicinal Products for Human Use recommends approval of NUEDEXTA for the treatment of pseudobulbar affect. The company says the positive opinion is an important milestone on the road to getting "the only evidence-based treatment for PBA approved in the European Union."